Today: 13 June 2026
Bank of America stock (BAC) holds near 52-week high after accounting change trims key capital ratio
7 January 2026
2 mins read

Bank of America stock (BAC) holds near 52-week high after accounting change trims key capital ratio

New York, Jan 6, 2026, 20:14 EST — Market closed

  • Bank said accounting method shift would have lowered its CET1 ratio by 13 basis points as of Sept. 30, 2025
  • Shares closed up 0.63% at $57.25 on Tuesday, about 0.5% below the 52-week high
  • Next catalysts include U.S. jobs data on Jan. 9 and Bank of America earnings on Jan. 14

Bank of America Corp said it changed accounting methods for certain tax-related equity investments, an adjustment that would have cut its common equity tier 1 (CET1) ratio — a key measure of bank capital — by 13 basis points as of Sept. 30, 2025, on a pro forma basis. Applied retrospectively, retained earnings as of Sept. 30 fell $1.7 billion and CET1 capital would have decreased about $2.1 billion, it said; it also estimated its third-quarter effective tax rate would have been about 20% versus 10.4% previously reported. The lender said the new methods are preferable because they “better align the financial statement presentation with the economic impact” of the investments. SEC

The tweak lands ahead of a busy stretch for big banks, when investors and regulators scrutinize capital buffers that underpin dividends and share buybacks. A basis point is one-hundredth of a percentage point.

The shift also changes where tax benefits from those investments show up in the income statement, moving amounts between noninterest income and income tax expense. That can blur quarter-to-quarter comparisons even if cash flow does not change, raising the bar for clear disclosures as earnings season begins.

Bank of America shares rose 0.63% to close at $57.25 on Tuesday, after touching a 52-week high of $57.55 a day earlier. The 52-week low was $33.06, FinanceCharts data show.

Other large U.S. banks were mixed, with JPMorgan Chase up 0.62% and Wells Fargo little changed while Citigroup slipped 0.65%, MarketWatch data showed. The S&P 500 gained 0.62% and the Dow industrials rose 0.99%.

On the Street, Barclays analyst Jason Goldberg raised his price target on Bank of America to $71 from $59 and maintained an “Overweight” rating on Jan. 5, according to GuruFocus. The same report put the average one-year target price from 25 analysts at $58.54, with estimates ranging from $45 to $68. GuruFocus

The next major catalyst is Jan. 14, when Bank of America is scheduled to report fourth-quarter results, releasing numbers around 6:45 a.m. ET and holding a conference call at 8:30 a.m., the bank has said. Investors typically focus on net interest income — what the bank earns on loans minus what it pays on deposits — as well as credit costs and expenses.

Macro data could also steer bank shares through Treasury yields: the U.S. jobs report is due on Jan. 9 and the CPI inflation report for December is set for Jan. 13, according to the Labor Department’s statistics agency calendar. The Federal Reserve’s next policy meeting is scheduled for Jan. 27-28.

But investors may treat any perceived hit to capital headroom cautiously, especially if the accounting shift complicates trendlines in revenue, tax rate and capital going into earnings. A sharper downturn in consumer credit or a fast drop in long-term rates would also pressure profit expectations for large lenders.

Traders will look to Bank of America’s Jan. 14 results for updated guidance and for

Stock Market Today

  • Telix Pharmaceuticals Phase 3 ProstACT Safety Data Boosts Investment Outlook
    June 12, 2026, 8:05 PM EDT. Telix Pharmaceuticals (ASX:TLX) announced early Phase 3 ProstACT trial data for TLX591-Tx in metastatic castration-resistant prostate cancer, demonstrating an acceptable safety and tolerability profile with no new safety concerns. The lower kidney and salivary gland exposure compared to existing therapies could signal a differentiated advantage. This supports Telix's shift from diagnostics to higher-value therapeutics but hinges on upcoming pivotal trial results. A new U.S. collaboration with United Imaging aims to enhance theranostics workflow and commercial scale. Despite promising clinical progress, risks include regulatory scrutiny following an SEC subpoena over prostate cancer disclosures. Analysts forecast 22.7% annual revenue growth to A$1.2 billion by 2029, with an 85% upside to Telix's current price. Market watchers weigh potential regulatory and execution challenges against long-term growth prospects in theranostics.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Gold price nears record and lifts Newmont stock after hours — what investors watch next
Previous Story

Gold price nears record and lifts Newmont stock after hours — what investors watch next

Intel stock today: INTC steadies before the bell as CES “Panther Lake” chips put 18A under the microscope
Next Story

Intel stock today: INTC steadies before the bell as CES “Panther Lake” chips put 18A under the microscope

Go toTop